Journal article
Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial
Abstract
We conducted an analysis of indirect costs alongside the LY.12 randomized trial in patients with relapsed or refractory (R/R) aggressive non-Hodgkin lymphoma (NHL). Lost productivity data for Canadian patients and caregivers in the trial were collected at baseline and with each chemotherapy cycle pre-transplant, using an adapted Lost Productivity questionnaire. Mean per patient indirect costs were CAD 2999 for patients in the GDP arm and CAD …
Authors
Prica A; Hay AE; Crump M; Mittmann N; Shepherd LE; Meyer RM; Imrie KI; Risebrough N; Djurfeldt M; Chen BE
Journal
Current Oncology, Vol. 28, No. 2, pp. 1256–1261
Publisher
MDPI
DOI
10.3390/curroncol28020119
ISSN
1198-0052